in reducing HIV infection in DCs were compared. Results are depicted as the mean 6 SD from seven donors. Significant differences were assessed by the non-parametric Mann-Whitney U- test and are indicated by *p,0.05. Non-significant differences, NS. (EPS) Figure S2 Dose-response effect of ApoAct on the per- centage of HIV-infected DCs. A dose-response assessment was performed by adding decreasing amounts of ApoAct (allogeneic) starting with a 1:1 DC:ApoAct ratio. The number of DCs was kept constant, and the ApoAct were serially diluted (n = 4). HIV p24 expression in DCs was assessed by flow cytometry after 7 days. Data represent the mean 6 SD from four different donors. (EPS) Figure S3 Reduced percentage of HIV infection in DCs co-cultured with ApoAct both pre- and post-HIVBaL exposure. Immature DCs were exposed to HIVBaL (HIV) or both HIV and apoptotic anti-CD3– and anti-CD28–activated allogeneic CD4+ T cells (ApoAct). (A) ApoAct were added at the same time as the virus (ApoAct+HIV) or at 30 minutes, 1 hour, or 2 hours prior to addition of HIV. Conversely, in some cultures the DCs were first incubated with HIV for 30 minutes, 1 hour, or 2 hours prior to addition of ApoAct. The percentage of infected DCs was assessed by flow cytometry of intracellular p24 staining after 7 days. The resulting mean 6 SD from four donors is shown. (B) Longer kinetic experiments were also performed by incubating DCs with HIV for 16 hours before adding the ApoAct, or by incubating the DCs for 16 hours with ApoAct before adding the virus. The mean 6 SD from four donors is shown. No statistical analyses were performed. (EPS) Figure S4 ApoAct inhibit infection of different HIV isolates in DCs. Immature DCs were exposed to HIVBaL; HIVIIIB; or two different primary isolates, 207 and 208, in the presence (white bars) or absence (black bars) of ApoAct (allogeneic). The percentage of infected DCs was assessed by flow cytometry of References 1. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245–252. 2. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621–667. 3. Bakri Y, Schiffer C, Zennou V, Charneau P, Kahn E, et al. (2001) The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication. J Immunol 166: 3780–3788. 4. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440: 808–12. 5. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, et al. (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887–892. 6. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 11: 419–426. 7. Piguet V, Steinman RM (2007) The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol 28: 503–510. 8. Coleman CM, Wu L (2009) HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6: 51. 9. Hu Q, Frank I, Williams V, Santos JJ, Watts P, et al. (2004) Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 199: 1065–1075. 10. Cavrois M, Neidleman J, Kreisberg JF, Fenard D, Callebaut C, et al. (2006) Human immunodeficiency virus fusion to dendritic cells declines as cells mature. J Virol 80: 1992–1999. 11. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM (1998) Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 72: 2733–2737. 12. Alkhatib G (2009) The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 4: 96–103. Apoptotic Activated T Cells Inhibit HIV in DCs intracellular p24 staining after 7 days. Data represent the mean 6 SD from two different donors. (EPS) Figure S5 APOBEC3G mRNA expression are induced after co-culturing with either LPS or ApoAct after normalization to two different reference genes. Real-time PCR was used to determine fold changes in mRNA for APOBEC3G in DCs co-cultured with LPS, resting apoptotic allogeneic CD4+ T cells (ApoRest), or activated apoptotic allogeneic CD4+ T cells (ApoAct). Cycle threshold values for APOBEC3G were normalized either to the value for GAPDH or 18s RNA. mRNA levels were compared with DCs cultured in medium for 24 hours. Data represent the mean 6 SD from four different donors. (EPS) Figure S6 Efficiency of APOBEC3G silencing in DCs by siRNA. (A) To silence APOBEC3G, the DCs were either transfected with APOBEC3G specific siRNA (siA3G), Non- Targeting siRNA (siNonTarget) or not exposed to the transfection procedure. Real-time PCR was used to determine the efficiency of the silencing by measuring the fold changes in mRNA for APOBEC3G in DCs co-cultured with LPS, resting apoptotic allogeneic CD4+ T cells (ApoRest), or activated apoptotic allogeneic CD4+ T cells (ApoAct). The mRNA levels were compared with DCs cultured in medium for 24 hours. Results are representative of two donors. (B) Supernatant from DCs co-cultured with LPS, ApoRest, or ApoAct that were either transfected with siA3G, siNonTarget or not exposed to the transfection procedure, were collected after 24 hours and analyzed for the presence of TNF-a by performing an ELISA. Results are representative of two donors. (EPS) Author Contributions Conceived and designed the experiments: LW-J UJ VM AES BM A-LS. Performed the experiments: LW-J UJ VM AES SKP BM JF. Analyzed the data: LW-J UJ VM AES SKP BM A-LS. Contributed reagents/materials/ analysis tools: JF. Wrote the paper: LW-J UJ VM A-LS. 13. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, et al. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells [see comments]. Science 270: 1811–1815. 14. Vicenzi E, Biswas P, Mengozzi M, Poli G (1997) Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication. J Leukoc Biol 62: 34–40. 15. Geonnotti AR, Bilska M, Yuan X, Ochsenbauer C, Edmonds TG, et al. (2010) Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. AIDS Res Hum Retroviruses 26: 279–291. 16. Folks T, Powell DM, Lightfoote MM, Benn S, Martin MA, et al. (1986) Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implica- tions for latency. Science 231: 600–602. 17. Clouse KA, Powell D, Washington I, Poli G, Strebel K, et al. (1989) Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142: 431–438. 18. Osborn L, Kunkel S, Nabel GJ (1989) Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A 86: 2336–2340. 19. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB (1989) Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A 86: 5974–5978. 20. Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ (1989) Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature 339: 70–73. 21. Herbein G, Montaner LJ, Gordon S (1996) Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. J Virol 70: 7388–7397. PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e21171